ArticleJournal of the American Heart Association2025
Association Between Elevated Total Homocysteine and Heart Failure Risk in the Multi-Ethnic Study of Atherosclerosis Cohort.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Longitudinal associations of one-carbon metabolism biomarkers with biological and epigenetic aging in older adults in India.GeroScience · 2026Article
- The plasma protein profile of left ventricular diastolic function.Scientific reports · 2026Article
- Myocardial metabolic remodeling in human end-stage ischemic and non-ischemic cardiomyopathy.Journal of molecular and cellular cardiology · 2026Article
- Abdominal Obesity, Hepatic Steatosis, Oxidative Stress and Diastolic Dysfunction in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.International journal of molecular sciences · 2026Article
- Diagnostic Potential of Metabolomic and Proteomic Biomarkers in Cardiology-A Narrative Review.Biomedicines · 2026Review
- Alpha-7 nicotinic acetylcholine receptor: targeting the interplay between inflammation, renin-angiotensin aldosterone system, and nervous system for the novel treatment of heart failure.Frontiers in pharmacology · 2026Review
- High-Sensitivity Troponins and Homocysteine: Combined Biomarkers for Better Prediction of Cardiovascular Events.International journal of molecular sciences · 2025Review
- Transsulfuration Pathway Products and HInternational journal of molecular sciences · 2025Review
- The relationship between thyroid hormones sensitivity and hyperhomocysteinemia: a cross-sectional study based on Chinese health check-up population.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLimited studies show an association between elevated total homocysteine (tHcy) and heart failure (HF) risk, but no studies have assessed whether this association differs by HF subtype. This study examines the relationship between tHcy, HF overall, and HF subtype (HF with preserved ejection fraction [HFpEF] and HF with reduced ejection fraction) in the Multi-Ethnic Study of Atherosclerosis cohort.
methodsMulti-Ethnic Study of Atherosclerosis participants with baseline tHcy and HF data were included (N=6765). Cox proportional hazards regression was used to calculate hazard ratios and 95% CI for tHcy and risk of HF. Models were stratified by impaired fasting glucose/type 2 diabetes status, and the combined impact of elevated tHcy and impaired fasting glucose/type 2 diabetes on HF incidence was examined.
resultsElevated tHcy (>12 μmol/L) was statistically significantly associated with HF overall and HFpEF, and conferred a higher risk for HF overall among individuals with dysglycemia impaired fasting glucose/type 2 diabetes compared with those with normoglycemia. Additionally, there was a statistically significant increased risk of HF overall and HF with reduced ejection fraction and a trend towards increased risk of HFpEF in individuals with both elevated tHcy and dysglycemia. tHcy appears to be a more significant contributor to HFpEF risk than dysglycemia, whereas dysglycemia seems to be more important in driving HF with reduced ejection fraction risk.
conclusionsOur study confirms an association between hyperhomocysteinemia and HF risk in a large, multi-ethnic cohort. This is the first study to demonstrate that the impact of tHcy differs by HF subtype and appears to contribute more to HFpEF risk than HF with reduced ejection fraction risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.